Aging cells secrete substances known to promote the growth of cancer cells. The development of drugs that can selectively kill these cells or inhibit the secretion of substances is ongoing.
Zentalis Pharmaceuticals said it would cut 40% of its workforce as part of a restructuring to support the late-stage development of its cancer-drug azenosertib.